drugset / Trial / NCT05954988
A Study to Evaluate LTI-03 in Newly Diagnosed Idiopathic Pulmonary Fibrosis (IPF) Patients
RandomizedSequentialQuadruple-blindOther
Summary
This study will assess the safety and tolerability of inhaled LTI-03 in treatment naïve participants with newly diagnosed IPF.
Timeline
- Start
- 2023-07-06
- Primary completion
- 2024-09-25
- Completion
- 2024-09-25
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | LTI-03 | Peptide | 2.5 mg | Inhaled |
| Subject | LTI-03 | Peptide | 5 mg | Inhaled |